VCEL Stock Analysis: Buy, Sell, or Hold?
VCEL - Vericel Corporation
$47.49
0.49 (1.04%)
▲
5d:
+2.0%
30d:
+27.05%
90d:
+40.92%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Jul 30, 2026
15d
Get Alerted When VCEL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: VCEL shows positive signals but monitor for confirmation. Market pricing in 2.2% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: VCEL shows positive signals but monitor for confirmation. Market pricing in 2.2% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$41.48
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$25.76
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: VCEL is currently trading at $47.49, which is considered extended relative to its 30-day fair value range of $38.08 to $46.34. The stock's valuation (Forward PE: 55.7) is in line with its historical norms (52.2). At these levels, the market is pricing in 2.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, VCEL is in a uptrend. The price is approaching resistance at $48.33. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: VCEL has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $55.43 (+16.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, VCEL is in a uptrend. The price is approaching resistance at $48.33. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: VCEL has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $55.43 (+16.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$38.08 -
$46.34
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
68.1%
Protect Your Profits
VCEL is technically overbought (RSI 71). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($55.43)
- NEUTRAL: Market pricing in 2.2% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$38.08 -
$46.34
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$3.15
(6.6%)
Support & Resistance Levels
Support Level
$43.53
Resistance Level
$48.33
Current Trend
Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
55.74
Wall Street Target
$55.43
(+16.7%)
Revenue Growth (YoY)
30.1%
Earnings Growth (YoY)
18.9%
Profit Margin
7.3%
Valuation Premium vs History
+2.2% premium
PE vs Historical
55.7 vs 52.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.2%
(market-implied from PE analysis)
1-Year Target
$48.53
(+2%)
2-Year Target
$49.60
(+4%)
3-Year Target
$50.69
(+7%)
3-Yr Target (if PE normalizes)
(PE: 56→52)
PE COMPRESSION
$47.47
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 55.7, Growth: 88.5%)
$160.28
(+238%)
Base:
(SPY PE: 21.8, Growth: 88.5%)
$62.63
(+32%)
Bear:
(PE: 18.5, Growth: 88.5%)
$53.23
(+12%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (99x PE), but valuation improves significantly next year (56x PE) as earnings recover.
Forward PE: 99.01 | Forward EPS (Implied): $0.48
Bull Case
$57.34
(+21%)
Analyst growth 15.0%, PE expands to 104.0
Base Case
$47.49
(0%)
Market implied 0.0%, PE stable at 99.0
Bear Case
$36.33
(-24%)
Severe decline -15.0%, PE contracts to 89.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 14, 2026 2:08 AM ET
Data refreshes hourly during market hours. Next update: 3:08 AM
Data refreshes hourly during market hours. Next update: 3:08 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VCEL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Jonathan Mark Hopper
SELL
3472 shares
2026-04-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$413 | 54 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 61 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 55 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
Advanced VCEL Option Strategies
Professional options setups generated by AI based on today's VCEL price and gamma walls.
